January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences ...

Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 ...

Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.

The pharma will vie for amlitelimab’s approval, despite the COAST 2 trial missing a co-primary endpoint.

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing ...

Bausch Health Companies Inc. was hit by a failed RED-C Phase 3, weak cash flow vs. interest, and a risky pipeline. Click for ...

Virginia university leads trial testing ARD-201, an oral drug to maintain weight loss after stopping GLP-1 treatments like ...

PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics, Inc. ('Alveus”), a clinical-stage biotechnology company developing next-generation therapies ...

As of 22 January, 19 of the 23 patients who have received treatment are still alive, with the longest evaluable survival ...

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and ...

Community screening study could prevent emergency diagnoses in children with type 1 diabetes: United Kingdom Friday, January 23, 2026, 13:00 Hrs [IST] An NIHR delivered study, whi ...

Both platforms are backed by over 50 peer-reviewed publications representing decades of development. The addressable markets span multiple areas: Alzheimer's disease ($32.8 billion by 2033), ...